Practical Approaches and Knowledge Gaps in the Care for Children With Leukodystrophies

Stephanie R Keller1, Eric J Mallack2, Jennifer P Rubin3

  • 1Department of Pediatrics, Division of Pediatric Neurology, 1371Emory University/Children's Healthcare of Atlanta, Atlanta, GA, USA.

Journal of Child Neurology
|September 3, 2020
PubMed

Insights

This study provides neurologic care guidelines for leukodystrophies, a group of rare genetic disorders. Recommendations focus on sleep, pain, seizures, and cognition, tailored to disease severity stages.

Area of Science:

  • Neurology
  • Genetics
  • Pediatric Disorders

Background:

  • Leukodystrophies are rare neurodegenerative genetic disorders affecting 1 in 7500 individuals.
  • Existing neurologic care guidelines are limited, hindering physician and caregiver consensus.
  • Patient advocacy meetings identified critical knowledge gaps in managing these conditions.

Purpose of the Study:

  • To develop evidence-based guidelines for neurologic care in leukodystrophies.
  • To address core domains prioritized by families: sleep, pain, seizures/epilepsy, and language/cognition.
  • To establish a severity-based system for tailored patient management.

Main Methods:

  • Literature review and synthesis of best practices from 2016-2018 patient advocacy meetings.
  • Development of a disease severity classification system (presymptomatic, early, intermediate, advanced symptomatic).
  • Identification of four key neurologic domains for focused recommendations.

Main Results:

  • Established a framework for neurologic care based on defined stages of leukodystrophy severity.
  • Prioritized recommendations across sleep, pain, seizures/epilepsy, and language/cognition domains.
  • Highlighted the need for individualized care plans considering disease specifics and knowledge gaps.

Conclusions:

  • Neurologic care for leukodystrophies requires tailored strategies aligned with disease severity stages.
  • Standardized tools can aid treatment guidance without excessively burdening families.
  • Addressing identified knowledge gaps is crucial for improving patient outcomes in leukodystrophies.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.3K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
147
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
172
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
148